Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of
transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a …

Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …

The emergence of Omicron sublineages impacts the therapeutic efficacy of anti-severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) …

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy
providing excellent remission rates and durable disease control for patients with …

Background Intramuscular AZD7442 (tixagevimab–cilgavimab [Evusheld; AstraZeneca]) has
been found effective among immunocompromised individuals (ICIs) in reducing SARS-CoV …

Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …

Some proportions of populations, such as immunocompromised patients and organ
transplant recipients might have inadequate immune responses to the vaccine for …

Immunocompromised patients, such as those with a haematological malignancy, are at
higher risk of SARS‐CoV‐2 infection, severe outcomes and mortality. Tixagevimab …

Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

Since the emergence of the Omicron variant of SARS-CoV-2, though considered less
virulent, hospitalization and death rates among immunocompromised patients remain high …